Vascul Pharmacol 138:106855
However, recent randomized clinical trials have reported significant weight loss associated with newer medications such as semaglutide, which is a glucagon-like peptide (GLP) 1 receptor agonist, and tirzepatide, also a or GLP-1 receptor agonist and a gastric inhibitory polypeptide agonist, among obese individuals irrespective of type 2 diabetes status
In clinical practice, that means more predictable hunger cues, smaller portions, and fewer cravings for ultra-processed foods
While it can significantly improve energy, libido, mood, and overall quality of life, like any medical treatment, it may carry some side effectsone of which is polycythemia
GLP-1 medications, like semaglutide, mimic this function, helping you feel satisfied with smaller meal portions
Rhonda Patrick: And your muscles are basically contracting and producing heat from that, but that's just not very efficient